Clinical trials
Full profile accessFollow clinical development from study design and recruitment through results.
- Trial phase
- Status
- Readouts
Drug intelligence / Profile preview
Carvedilol + alverine is a combination of two small molecule drugs, each with distinct mechanisms and indications. Carvedilol is a non-selective beta-adrenergic antagonist (beta-blocker) with additional alpha-1 adrenergic blocking activity, primarily used to treat mild to severe chronic heart failure, hypertension, and left ventricular dysfunction following myocardial infarction[1][3][5]. It works by slowing the heart rate and relaxing blood vessels, thereby reducing blood pressure and cardiac workload. Alverine is a smooth muscle relaxant indicated for the relief of cramps or spasms in the stomach and intestines, commonly used in conditions such as irritable bowel syndrome (IBS) and other gastrointestinal disorders[9]. It acts directly on gut smooth muscle to prevent spasms that cause pain or discomfort. The combination of these agents does not represent an established fixed-dose product but would theoretically combine cardiovascular effects (from carvedilol) with antispasmodic effects on the gastrointestinal tract (from alverine).
Beyond the preview
Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.
Follow clinical development from study design and recruitment through results.
Explore development by indication, patient population, and geography.
Trace asset ownership, licensing agreements, and commercial partnerships.
Explore the patent landscape and regulatory exclusivity around an asset.
Compare development programs by target, modality, and indication.
Connect source evidence and development news to your research questions.
See how Gosset can support your research on carvedilol + alverine.